GNF-Pf-3446

ID: ALA582486

Chembl Id: CHEMBL582486

Cas Number: 904576-65-4

PubChem CID: 40504628

Max Phase: Preclinical

Molecular Formula: C16H16ClN7O

Molecular Weight: 357.81

Molecule Type: Small molecule

Names and Identifiers

Synonyms: GNF-Pf-3446 | MMV665917 | GNF-Pf-3446|904576-65-4|MMV665917|4-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-N-(4-chlorophenyl)piperazine-1-carboxamide|N-(4-chlorophenyl)-4-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperazine-1-carboxamide|N-(4-chlorophenyl)-4-{[1,2,4]triazolo[4,3-b]pyridazin-6-yl}piperazine-1-carboxamide|CHEMBL582486|SCHEMBL18126656|CCG-31218|NSC766495|AKOS024499167|NSC-766495|SR-01000098684|SR-01000098684-1|F5123-0125

Canonical SMILES:  O=C(Nc1ccc(Cl)cc1)N1CCN(c2ccc3nncn3n2)CC1

Standard InChI:  InChI=1S/C16H16ClN7O/c17-12-1-3-13(4-2-12)19-16(25)23-9-7-22(8-10-23)15-6-5-14-20-18-11-24(14)21-15/h1-6,11H,7-10H2,(H,19,25)

Standard InChI Key:  ZDXWENNHTOBFEW-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA582486

   4-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-N-(4-chlorophenyl)piperazine-1-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 357.81

Molecular Weight (Monoisotopic): 357.1105

AlogP: 2.13

#Rotatable Bonds: 2

Polar Surface Area: 78.66

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.37

CX Basic pKa: 1.45

CX LogP: 1.98

CX LogD: 1.98

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.76

Np Likeness Score: -2.91

References

1. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, Nagle A, Adrián F, Matzen JT, Anderson P, Nam TG, Gray NS, Chatterjee A, Janes J, Yan SF, Trager R, Caldwell JS, Schultz PG, Zhou Y, Winzeler EA..  (2008)  In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,  105  (26): [PMID:18579783] [10.1073/pnas.0802982105]

2. Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA..  (2011)  Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,  334  (6061): [PMID:22096101] [10.1126/science.1211936]

3. Simon Macdonald, Paul Willis, Paul Kowalczyk, Thomas Spangenberg, Jeremy Burrows and Tim Wells. Medicines for Malaria Venture (MMV), PO Box 1826, 20, rte de Pré-Bois, 1215 Geneva 15, Switzerland and SCYNEXIS Inc. P.O. Box 12878 Research Triangle Park, North Carolina 27709-2878 USA. Malaria Box,  [10.6019/CHEMBL2028040]

4. Ben Gold, Thulasi Warrier, Selin Somersan, Landys Lopez-Quezada, Julia Roberts, David Little and Carl Nathan.. Malaria Box Tuberculosis Screening Data,  [10.6019/CHEMBL2094260]

5. Conor Caffrey and Brian Suzuki; Center for Discovery and Innovation in Parasitic Diseases, Dept. of Pathology, University of California San Francisco (www.cdipd.org).. Malaria Box Schistosomiasis Screening Data,  [10.6019/CHEMBL2363022]

6. UCSF DeRisi Lab. UCSF DeRisi Lab MMV Box Apicoplast Screening,  [10.6019/CHEMBL2448809]

7. University of Vermont. MMV Box Cryptosporidium parvum screening set,  [10.6019/CHEMBL3137356]

8. Northwick Park. MMV Box Onchocerca lienalis screening set,  [10.6019/CHEMBL3137381]

9. Boyom, F.F., Fokou, P.V.T., Tchokouaha, L.R.Y., Spangenberg, T., Mfopa, A.N., Kouipou, R.M.T., Mbouna, C.J., Donkeng Donfack, V.F., Zollo, P.H.A. University of Yaoundé, IMPM Yaoundé and MMV.. MMV Malaria Box screening against Toxoplasma gondii and Entamoeba histolytica.,  [10.6019/CHEMBL3301448]

10. Imperial-Medicines for Malaria Venture Centre of Excellence, Imperial College, London.. MMV Malaria Box gametocyte functional viability assay screening.,  [10.6019/CHEMBL3301451]

11. Medicines for Malaria Venture.. MMV Malaria Box hERG screening.,  [10.6019/CHEMBL3301458]

12. Hui Lab, SGC, University of Toronto, Canada.. MMV Malaria Box thermal shift screening.,  [10.6019/CHEMBL3301461]

13. Igarashi Lab, National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan. MMV Malaria Box anti-babesial screening.,  [10.6019/CHEMBL3301464]

14. Kaiser Lab, University Hospital Essen, Germany.. MMV Malaria Box screening against Plasmodium falciparum Deoxyhypusine hydroxylase,  [10.6019/CHEMBL3301470]

15. Ketas, T., Moore, J.P., Weill Cornell Medical College, USA.. MMV Malaria Box HIV and cytotoxicity screening.,  [10.6019/CHEMBL3301472]

16. National Cancer Institute, NIH.. MMV Malaria Box screening against the the NCI60 panel of human tumor cell lines.,  [10.6019/CHEMBL3301486]

17. St Onge, R.P. Yeast Chemical Genomics Laboratory, Stanford Genome Technology Center, Stanford University.. MMV Malaria Box yeast growth screening.,  [10.6019/CHEMBL3301546]

18. Poulsen, S-A., Andrews, K.T., Tonissen, K.F., Nawaratna, S., Eskitis Institute for Drug Discovery, Griffith University, Australia.. MMV Mararia Box screening against P. falciparum asexual stage parasites under hypoxia and bicarbonate modified culture conditions.,  [10.6019/CHEMBL3301550]

19. Taramelli Lab, University of Milan, Italy.. MMV Malaria Box screening in pLDH viability assay against Plasmodium falciparum gametocytes.,  [10.6019/CHEMBL3301555]

20. Van Voorhis Lab, University of Washington, USA.. MMV Box screening against Plasmodium falciparum protein kinases and aminoacyl tRNA synthetases.,  [10.6019/CHEMBL3301562]

21. Horrocks lab, Keele University, UK.. MMV box screening in the Dd2 P. falciparum strain,  [10.6019/CHEMBL3392922]

22. LT Jensen lab, Mahidol University, Thailand (submitted by: Laran T. Jensen, Worathad Chindaudomsate, Amornrat Naranuntarat Jensen). MMV box selection for compounds with potential use in combination with artemisinin using S. cerevisiae,  [10.6019/CHEMBL3392924]

23. TropIQ Health Sciences. MMV Malaria Box gametocyte standard membrane feeding assay screening.,  [10.6019/CHEMBL3430850]

24. St. Jude Leishmania screening dataset.,  [10.6019/CHEMBL3433997]

25. Oboh E, Schubert TJ, Teixeira JE, Stebbins EE, Miller P, Philo E, Thakellapalli H, Campbell SD, Griggs DW, Huston CD, Meyers MJ..  (2021)  Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin.,  64  (15.0): [PMID:34342443] [10.1021/acs.jmedchem.1c01136]

26. Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ..  (2023)  Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.,  86  [PMID:37148788] [10.1016/j.bmc.2023.117295]

Source

Source(4):

• Scientific Literature
• Novartis Malaria Screening
• MMV Malaria Box
• St Jude Leishmania Screening